Breakdown | |||||
TTM | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
283.32M | 303.91M | 338.75M | 316.22M | 291.01M | 264.16M | Gross Profit |
151.43M | 154.70M | 174.25M | 165.73M | 156.79M | 150.27M | EBIT |
-25.46M | -192.44M | -19.23M | -19.01M | -14.87M | -14.17M | EBITDA |
-7.79M | -14.29M | 12.19M | 11.13M | -8.90M | -143.74M | Net Income Common Stockholders |
-41.39M | -184.35M | -52.44M | -26.55M | -31.55M | -165.79M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
44.76M | 76.06M | 44.62M | 28.82M | 48.16M | 54.44M | Total Assets |
285.42M | 317.67M | 532.64M | 552.75M | 561.44M | 595.51M | Total Debt |
5.00M | 5.91M | 49.82M | 33.78M | 20.00M | 40.84M | Net Debt |
-39.76M | -71.33M | 5.20M | 4.96M | -28.16M | -13.60M | Total Liabilities |
99.55M | 112.08M | 154.34M | 128.26M | 121.98M | 139.64M | Stockholders Equity |
185.87M | 205.59M | 378.30M | 424.49M | 439.46M | 455.87M |
Cash Flow | Free Cash Flow | ||||
-33.21M | -33.93M | -4.27M | -11.49M | 10.38M | -22.14M | Operating Cash Flow |
-23.94M | -28.16M | 78.00K | -7.19M | 24.09M | -14.55M | Investing Cash Flow |
-9.89M | 123.72M | -9.75M | -19.31M | -13.71M | -63.34M | Financing Cash Flow |
515.00K | -64.25M | 25.42M | 7.68M | -16.99M | -95.24M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
75 Outperform | $1.91B | 43.82 | 13.87% | 0.79% | 13.63% | 44.78% | |
64 Neutral | $5.29B | 44.16 | 9.32% | ― | 8.07% | 26.17% | |
61 Neutral | $5.80B | 87.79 | 1.61% | 1.05% | 2.45% | -80.87% | |
55 Neutral | $3.36B | ― | -5.76% | ― | 5.28% | -292.14% | |
51 Neutral | $375.61M | ― | -20.46% | ― | -12.56% | 78.70% | |
51 Neutral | $5.20B | 3.18 | -40.80% | 2.96% | 17.66% | 1.94% | |
49 Neutral | $815.35M | 55.81 | -5.16% | ― | -2.64% | -193.31% |
On April 2, 2025, AngioDynamics will host a virtual Cardiovascular Investor Event, highlighting its innovative technologies and improved patient outcomes in cardiovascular care. The event underscores AngioDynamics’ strategic focus on growth within the high-growth cardiovascular disease market, leveraging its comprehensive portfolio and differentiated technologies to strengthen its competitive position.
AngioDynamics reported its fiscal third quarter 2025 results, highlighting a 9.2% increase in net sales to $72.0 million, driven by a 22.2% growth in MedTech sales. The company achieved a GAAP gross margin of 54.0% and improved its adjusted EBITDA to $1.3 million, reflecting strategic focus on MedTech markets. Key developments include FDA clearance for the NanoKnife System for prostate tissue ablation and the initiation of the AMBITION BTK trial for the Auryon Atherectomy System. AngioDynamics also secured a $25 million revolving line of credit from J.P. Morgan, enhancing financial flexibility.